The first drug to be developed against CTLA-4 was ipilimumab, a mAb capable of antagonizing CTLA-4 (Figure 2C), for its use alone or in combination, in the treatment of melanoma, prostate, breast, renal and other cancers (26). Here, CTLA4 is linked to melanoma.